JP2003500367A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003500367A5 JP2003500367A5 JP2000619463A JP2000619463A JP2003500367A5 JP 2003500367 A5 JP2003500367 A5 JP 2003500367A5 JP 2000619463 A JP2000619463 A JP 2000619463A JP 2000619463 A JP2000619463 A JP 2000619463A JP 2003500367 A5 JP2003500367 A5 JP 2003500367A5
- Authority
- JP
- Japan
- Prior art keywords
- och
- conh
- nhco
- dye
- peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 description 24
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 21
- 108090000765 processed proteins & peptides Proteins 0.000 description 16
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- 238000000034 method Methods 0.000 description 10
- 239000007787 solid Substances 0.000 description 10
- RFFLAFLAYFXFSW-UHFFFAOYSA-N 1,2-dichlorobenzene Chemical compound ClC1=CC=CC=C1Cl RFFLAFLAYFXFSW-UHFFFAOYSA-N 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- 239000000562 conjugate Substances 0.000 description 6
- 229910052739 hydrogen Inorganic materials 0.000 description 6
- 239000001257 hydrogen Substances 0.000 description 6
- CFODQUSMSYDHBS-UHFFFAOYSA-N octreotate Chemical compound O=C1NC(CC=2C=CC=CC=2)C(=O)NC(CC=2[C]3C=CC=CC3=NC=2)C(=O)NC(CCCCN)C(=O)NC(C(C)O)C(=O)NC(C(=O)NC(C(O)C)C(O)=O)CSSCC1NC(=O)C(N)CC1=CC=CC=C1 CFODQUSMSYDHBS-UHFFFAOYSA-N 0.000 description 6
- 239000011347 resin Substances 0.000 description 6
- 229920005989 resin Polymers 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 102000002068 Glycopeptides Human genes 0.000 description 4
- 108010015899 Glycopeptides Proteins 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 4
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- -1 antibodies Proteins 0.000 description 4
- 229920001542 oligosaccharide Polymers 0.000 description 4
- 150000002482 oligosaccharides Chemical class 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 3
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 3
- 125000003118 aryl group Chemical group 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- DQJCDTNMLBYVAY-ZXXIYAEKSA-N (2S,5R,10R,13R)-16-{[(2R,3S,4R,5R)-3-{[(2S,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-(ethylamino)-6-hydroxy-2-(hydroxymethyl)oxan-4-yl]oxy}-5-(4-aminobutyl)-10-carbamoyl-2,13-dimethyl-4,7,12,15-tetraoxo-3,6,11,14-tetraazaheptadecan-1-oic acid Chemical compound NCCCC[C@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@@H](C)NC(=O)C(C)O[C@@H]1[C@@H](NCC)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DQJCDTNMLBYVAY-ZXXIYAEKSA-N 0.000 description 2
- DEQANNDTNATYII-OULOTJBUSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-n-[(2r,3r)-1,3-dihydroxybutan-2-yl]-7-[(1r)-1-hydroxyethyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 description 2
- QGKMIGUHVLGJBR-UHFFFAOYSA-M (4z)-1-(3-methylbutyl)-4-[[1-(3-methylbutyl)quinolin-1-ium-4-yl]methylidene]quinoline;iodide Chemical compound [I-].C12=CC=CC=C2N(CCC(C)C)C=CC1=CC1=CC=[N+](CCC(C)C)C2=CC=CC=C12 QGKMIGUHVLGJBR-UHFFFAOYSA-M 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- BDKLKNJTMLIAFE-UHFFFAOYSA-N 2-(3-fluorophenyl)-1,3-oxazole-4-carbaldehyde Chemical compound FC1=CC=CC(C=2OC=C(C=O)N=2)=C1 BDKLKNJTMLIAFE-UHFFFAOYSA-N 0.000 description 2
- 108010016076 Octreotide Proteins 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 125000004103 aminoalkyl group Chemical group 0.000 description 2
- 238000000149 argon plasma sintering Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- WFSXUTWNNVIIIG-ZPUQHVIOSA-N glutaconaldehyde Chemical compound O\C=C\C=C\C=O WFSXUTWNNVIIIG-ZPUQHVIOSA-N 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 150000002431 hydrogen Chemical class 0.000 description 2
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 2
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 2
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 2
- 230000031700 light absorption Effects 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 229960002700 octreotide Drugs 0.000 description 2
- 239000000863 peptide conjugate Substances 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 229940087562 sodium acetate trihydrate Drugs 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- HNKJADCVZUBCPG-UHFFFAOYSA-N thioanisole Chemical compound CSC1=CC=CC=C1 HNKJADCVZUBCPG-UHFFFAOYSA-N 0.000 description 2
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- GOLXRNDWAUTYKT-UHFFFAOYSA-N 3-(1H-indol-3-yl)propanoic acid Chemical compound C1=CC=C2C(CCC(=O)O)=CNC2=C1 GOLXRNDWAUTYKT-UHFFFAOYSA-N 0.000 description 1
- DHXNZYCXMFBMHE-UHFFFAOYSA-N 3-bromopropanoic acid Chemical compound OC(=O)CCBr DHXNZYCXMFBMHE-UHFFFAOYSA-N 0.000 description 1
- NVRVNSHHLPQGCU-UHFFFAOYSA-N 6-bromohexanoic acid Chemical compound OC(=O)CCCCCBr NVRVNSHHLPQGCU-UHFFFAOYSA-N 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- 102000013585 Bombesin Human genes 0.000 description 1
- 108010051479 Bombesin Proteins 0.000 description 1
- 102100025841 Cholecystokinin Human genes 0.000 description 1
- 101800001982 Cholecystokinin Proteins 0.000 description 1
- 208000003788 Neoplasm Micrometastasis Diseases 0.000 description 1
- 102400001103 Neurotensin Human genes 0.000 description 1
- 101800001814 Neurotensin Proteins 0.000 description 1
- 102000005157 Somatostatin Human genes 0.000 description 1
- 108010056088 Somatostatin Proteins 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- 108010003205 Vasoactive Intestinal Peptide Proteins 0.000 description 1
- 102400000015 Vasoactive intestinal peptide Human genes 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- DNDCVAGJPBKION-DOPDSADYSA-N bombesin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1NC2=CC=CC=C2C=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1NC(=O)CC1)C(C)C)C1=CN=CN1 DNDCVAGJPBKION-DOPDSADYSA-N 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 229940107137 cholecystokinin Drugs 0.000 description 1
- 150000004696 coordination complex Chemical class 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 238000001839 endoscopy Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- PCJGZPGTCUMMOT-ISULXFBGSA-N neurotensin Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 PCJGZPGTCUMMOT-ISULXFBGSA-N 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000002428 photodynamic therapy Methods 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
- 229960000553 somatostatin Drugs 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 229910052716 thallium Inorganic materials 0.000 description 1
- BKVIYDNLLOSFOA-UHFFFAOYSA-N thallium Chemical compound [Tl] BKVIYDNLLOSFOA-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 238000003325 tomography Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13506099P | 1999-05-20 | 1999-05-20 | |
| US60/135,060 | 1999-05-20 | ||
| US09/325,769 | 1999-06-04 | ||
| US09/325,769 US6217848B1 (en) | 1999-05-20 | 1999-06-04 | Cyanine and indocyanine dye bioconjugates for biomedical applications |
| PCT/US2000/011060 WO2000071162A2 (en) | 1999-05-20 | 2000-04-26 | Cyanine and indocyanine dye bioconjugates for biomedical applications |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003500367A JP2003500367A (ja) | 2003-01-07 |
| JP2003500367A5 true JP2003500367A5 (enExample) | 2010-09-24 |
Family
ID=26832945
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000619463A Pending JP2003500367A (ja) | 1999-05-20 | 2000-04-26 | 生物医学的適用のための新規なシアニンおよびインドシアニン染料バイオコンジュゲート |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US6217848B1 (enExample) |
| EP (2) | EP2058007A3 (enExample) |
| JP (1) | JP2003500367A (enExample) |
| AT (1) | ATE435662T1 (enExample) |
| AU (1) | AU4488800A (enExample) |
| CA (1) | CA2373475C (enExample) |
| DE (1) | DE60042522D1 (enExample) |
| DK (1) | DK1178830T3 (enExample) |
| ES (1) | ES2329542T3 (enExample) |
| PT (1) | PT1178830E (enExample) |
| WO (1) | WO2000071162A2 (enExample) |
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7175953B2 (en) * | 1999-04-09 | 2007-02-13 | Institute Fuer Diagnostik Forschung | Short-warp peptide-dye conjugate as contrast agent for optical diagnostic |
| US6630570B1 (en) * | 1999-04-09 | 2003-10-07 | Insitut für Diagnostikforschung GmbH | Short-chain peptide-dye conjugates as contrast media for optical diagnosis |
| US20050182434A1 (en) * | 2000-08-11 | 2005-08-18 | National Research Council Of Canada | Method and apparatus for performing intra-operative angiography |
| US6180085B1 (en) * | 2000-01-18 | 2001-01-30 | Mallinckrodt Inc. | Dyes |
| US6190641B1 (en) * | 2000-01-18 | 2001-02-20 | Mallinckrodt Inc. | Indocyanine dyes |
| US7230088B2 (en) * | 2001-07-03 | 2007-06-12 | Mallinckrodt, Inc. | Compounds for dual photodiagnosis and therapy |
| US7790144B2 (en) * | 2000-01-18 | 2010-09-07 | Mallinckrodt Inc. | Receptor-avid exogenous optical contrast and therapeutic agents |
| US7351807B2 (en) * | 2000-01-18 | 2008-04-01 | Mallinckrodt Inc. | Cyanine-sulfenates for dual phototherapy |
| US20030017164A1 (en) * | 2001-07-03 | 2003-01-23 | Mallinckrodt Inc. | Dye-azide compounds for dual phototherapy |
| US6673334B1 (en) * | 2000-10-16 | 2004-01-06 | Mallinkcrodt, Inc. | Light sensitive compounds for instant determination of organ function |
| US7556797B2 (en) * | 2000-10-16 | 2009-07-07 | Mallinckrodt Inc. | Minimally invasive physiological function monitoring agents |
| US6838074B2 (en) | 2001-08-08 | 2005-01-04 | Bristol-Myers Squibb Company | Simultaneous imaging of cardiac perfusion and a vitronectin receptor targeted imaging agent |
| US20030105300A1 (en) * | 2001-10-17 | 2003-06-05 | Mallinckrodt Inc. | Tumor targeted photodiagnostic-phototherapeutic agents |
| IL148921A0 (en) * | 2002-03-26 | 2002-09-12 | Peptor Ltd | Photo active backbone cyclized somatostatin analogs for optical imaging and photodynamic therapy |
| US20040022731A1 (en) * | 2002-04-26 | 2004-02-05 | Alexei Bogdanov | In vivo imaging of apoptosis |
| US6658143B2 (en) * | 2002-04-29 | 2003-12-02 | Amersham Biosciences Corp. | Ray-based image analysis for biological specimens |
| US7580185B2 (en) | 2002-08-28 | 2009-08-25 | Carl Zeiss Surgical Gmbh | Microscopy system, microscopy method and a method of treating an aneurysm |
| US7303741B2 (en) * | 2002-09-23 | 2007-12-04 | General Electric Company | Systems and methods for high-resolution in vivo imaging of biochemical activity in a living organism |
| US7226577B2 (en) | 2003-01-13 | 2007-06-05 | Bracco Imaging, S. P. A. | Gastrin releasing peptide compounds |
| DE10302787A1 (de) * | 2003-01-24 | 2004-08-12 | Schering Ag | Hydrophile, Thiol-reaktive Cyaninfarbstoffe und deren Konjugate mit Biomolekülen für die Fluoreszenzdiagnostik |
| WO2004080483A1 (en) * | 2003-03-10 | 2004-09-23 | Mpa Technologies, Inc. | Targeted agents for both photodiagnosis and photodynamic therapy |
| WO2005000218A2 (en) * | 2003-05-31 | 2005-01-06 | Washington University | Macrocyclic cyanine and indocyanine bioconjugates provide improved biomedical applications |
| NO20035681D0 (no) * | 2003-12-18 | 2003-12-18 | Amersham Health As | Optisk avbildning av lungekreft |
| NO20035682D0 (no) * | 2003-12-18 | 2003-12-18 | Amersham Health As | Optisk avbildning av ösofagkreft og Barretts ösofag |
| NO20035683D0 (no) * | 2003-12-18 | 2003-12-18 | Amersham Health As | Optisk avbildning av prostatakreft |
| DE102004022628A1 (de) * | 2004-05-07 | 2005-12-15 | Sensient Imaging Technologies Gmbh | FRET-Bioassay |
| US7585492B2 (en) * | 2004-05-18 | 2009-09-08 | Siemens Aktiengesellschaft | Biomolecular contrast agents for therapy success and dose monitoring in radiation therapy with proton or ion beams |
| US20050272967A1 (en) * | 2004-05-18 | 2005-12-08 | Siemens Aktiengesellschaft | Biomolecular contrast agents with multiple signal variance for therapy planning and control in radiation therapy with proton or ion beams |
| US20050259779A1 (en) * | 2004-05-18 | 2005-11-24 | Siemens Aktiengesellschaft | Biomolecular contrast agents for therapy optimization in radiation therapy with proton or ion beams |
| US20060239916A1 (en) * | 2005-01-07 | 2006-10-26 | Kai Licha | Use of cyanine dyes for the diagnosis of proliferative diseases |
| US20070122344A1 (en) | 2005-09-02 | 2007-05-31 | University Of Rochester Medical Center Office Of Technology Transfer | Intraoperative determination of nerve location |
| US20080161744A1 (en) | 2006-09-07 | 2008-07-03 | University Of Rochester Medical Center | Pre-And Intra-Operative Localization of Penile Sentinel Nodes |
| GB0714202D0 (en) * | 2007-07-20 | 2007-08-29 | Ge Healthcare Bio Sciences Ab | Isoelectric point markers |
| US8406860B2 (en) | 2008-01-25 | 2013-03-26 | Novadaq Technologies Inc. | Method for evaluating blush in myocardial tissue |
| US20090214436A1 (en) | 2008-02-18 | 2009-08-27 | Washington University | Dichromic fluorescent compounds |
| EP2100621A1 (en) | 2008-03-10 | 2009-09-16 | mivenion GmbH | Polyether polyol dendron conjugates with effector molecules for biological targeting |
| US10219742B2 (en) | 2008-04-14 | 2019-03-05 | Novadaq Technologies ULC | Locating and analyzing perforator flaps for plastic and reconstructive surgery |
| EP2687235A3 (en) | 2008-05-02 | 2014-11-05 | Novadaq Technologies Inc. | Methods for production and use of substance-loaded erythrocytes (S-LES) for observation and treatment of microvascular hemodynamics |
| US9433700B2 (en) | 2009-04-27 | 2016-09-06 | Medibeacon Inc. | Tissue sealant compositions, vascular closure devices, and uses thereof |
| US10492671B2 (en) | 2009-05-08 | 2019-12-03 | Novadaq Technologies ULC | Near infra red fluorescence imaging for visualization of blood vessels during endoscopic harvest |
| CN102573925B (zh) * | 2009-10-05 | 2015-08-05 | 佳能株式会社 | 光声成像用造影剂和使用所述光声成像用造影剂的光声成像方法 |
| WO2012054749A1 (en) | 2010-10-20 | 2012-04-26 | Li-Cor, Inc. | Cyanine dyes and their conjugates |
| WO2012123916A2 (en) | 2011-03-15 | 2012-09-20 | Ramot At Tel-Aviv University Ltd. | Activatable fluorogenic compounds and uses thereof as near infrared probes |
| DK2774625T3 (en) * | 2011-09-05 | 2017-06-12 | Hiroshi Maeda | POLYMER TYPE FLUORESCING MOLECULE PROBE |
| EP3553075B1 (en) | 2012-01-23 | 2025-01-08 | Washington University | Goggle imaging systems and methods |
| EP2863801B8 (en) | 2012-06-21 | 2024-06-12 | Stryker Corporation | Quantification and analysis of angiography and perfusion |
| ES2628529T3 (es) * | 2012-10-24 | 2017-08-03 | Tintes de cianina-azaindolina sustituidos con hidroxamato, y bioconjugados de los mismos | |
| KR101440109B1 (ko) | 2013-01-29 | 2014-09-12 | 부경대학교 산학협력단 | 위장관암의 림프절 전이 검출용 광음향 단층촬영 시스템 |
| AU2015327665B2 (en) | 2014-09-29 | 2018-09-27 | Stryker European Operations Limited | Imaging a target fluorophore in a biological material in the presence of autofluorescence |
| AU2014408488B2 (en) | 2014-10-09 | 2019-07-18 | Stryker European Operations Limited | Quantification of absolute blood flow in tissue using fluorescence-mediated photoplethysmography |
| US10806804B2 (en) * | 2015-05-06 | 2020-10-20 | Washington University | Compounds having RD targeting motifs and methods of use thereof |
| WO2018145193A1 (en) | 2017-02-10 | 2018-08-16 | Novadaq Technologies ULC | Open-field handheld fluorescence imaging systems and methods |
| EP4072598A4 (en) | 2019-12-13 | 2024-02-21 | Washington University | Near infrared fluorescent dyes, formulations and related methods |
| WO2023227601A1 (en) | 2022-05-23 | 2023-11-30 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Near-infrared fluorescent heptamethine dye conjugates with favorable bleaching properties |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5745457A (en) * | 1980-09-02 | 1982-03-15 | Fuji Photo Film Co Ltd | Microimmunological measuring method |
| JP3147992B2 (ja) * | 1992-05-29 | 2001-03-19 | イビデン株式会社 | 免疫測定用標識試薬 |
| JP3354975B2 (ja) * | 1992-10-06 | 2002-12-09 | イビデン株式会社 | 蛍光標識試薬および蛍光免疫測定法 |
| US5453505A (en) | 1994-06-30 | 1995-09-26 | Biometric Imaging, Inc. | N-heteroaromatic ion and iminium ion substituted cyanine dyes for use as fluorescence labels |
| DE4445065A1 (de) * | 1994-12-07 | 1996-06-13 | Diagnostikforschung Inst | Verfahren zur In-vivo-Diagnostik mittels NIR-Strahlung |
| US5962424A (en) * | 1995-02-21 | 1999-10-05 | Arch Development Corporation | Methods and compositions for targeting selectins |
| DE19602295C2 (de) * | 1996-01-23 | 2003-08-14 | Deutsches Krebsforsch | Verwendung eines Konjugats aus einer zur Fluoreszenz-fähigen Verbindung, Cyanurchlorid oder einem Derivat davon als Linker und einem Protein |
| WO1997033620A2 (de) * | 1996-03-15 | 1997-09-18 | Pulsion Verw. Gmbh & Co. Medical Systems Kg | Verbindungen zur behandlung von tumoren |
| DE19649971A1 (de) * | 1996-11-19 | 1998-05-28 | Diagnostikforschung Inst | Optische Diagnostika zur Diagnostik neurodegenerativer Krankheiten mittels Nahinfrarot-Strahlung (NIR-Strahlung) |
| WO1998048846A1 (en) | 1997-04-29 | 1998-11-05 | Nycomed Imaging As | Light imaging contrast agents |
| ES2213899T3 (es) | 1997-04-29 | 2004-09-01 | Amersham Health As | Agentes de contraste utilizados en tecnicas de formacion de imagen en base a la luz. |
| WO1999051284A2 (en) * | 1998-04-03 | 1999-10-14 | Mallinckrodt Inc. | Non-covalent bioconjugates useful for diagnosis and therapy |
| EP1131099A2 (en) * | 1999-01-15 | 2001-09-12 | Light Sciences Corporation | Noninvasive vascular therapy |
| US6602274B1 (en) * | 1999-01-15 | 2003-08-05 | Light Sciences Corporation | Targeted transcutaneous cancer therapy |
| WO2000041725A2 (en) * | 1999-01-15 | 2000-07-20 | Light Sciences Corporation | Therapeutic compositions for metabolic bone disorders or bone metastases |
-
1999
- 1999-06-04 US US09/325,769 patent/US6217848B1/en not_active Expired - Fee Related
-
2000
- 2000-04-26 DK DK00926343T patent/DK1178830T3/da active
- 2000-04-26 CA CA2373475A patent/CA2373475C/en not_active Expired - Lifetime
- 2000-04-26 AT AT00926343T patent/ATE435662T1/de not_active IP Right Cessation
- 2000-04-26 PT PT00926343T patent/PT1178830E/pt unknown
- 2000-04-26 WO PCT/US2000/011060 patent/WO2000071162A2/en not_active Ceased
- 2000-04-26 AU AU44888/00A patent/AU4488800A/en not_active Abandoned
- 2000-04-26 ES ES00926343T patent/ES2329542T3/es not_active Expired - Lifetime
- 2000-04-26 JP JP2000619463A patent/JP2003500367A/ja active Pending
- 2000-04-26 EP EP08075854A patent/EP2058007A3/en not_active Withdrawn
- 2000-04-26 EP EP00926343A patent/EP1178830B1/en not_active Expired - Lifetime
- 2000-04-26 DE DE60042522T patent/DE60042522D1/de not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003500367A5 (enExample) | ||
| CA2373475C (en) | Novel cyanine and indocyanine dye bioconjugates for biomedical applications | |
| US7201892B2 (en) | Pathological tissue detection and treatment employing targeted optical agents | |
| EP1559374B1 (en) | Cyanine dyes | |
| JP2003520215A (ja) | 生物医学的適用のための調整可能なインドシアニン染料 | |
| JP2003520868A (ja) | 造影用のデンドリマー前駆体染料 | |
| JP2011116773A (ja) | 親水性シアニン染料 | |
| US7850946B2 (en) | Macrocyclic cyanine and indocyanine bioconjugates provide improved biomedical applications | |
| JP2003535041A (ja) | 広用途の親水性染料 | |
| CA2463994A1 (en) | Carbocyanine dyes for tandem, photodiagnostic and therapeutic applications | |
| JP2003523371A (ja) | 新規のインドシアニン染料 | |
| CA2474920A1 (en) | Dye-bioconjugates for simultaneous optical diagnostic and therapeutic applications | |
| JP2005526863A (ja) | 腫瘍標的光学診断用−光学治療用成分 | |
| JP2003529632A (ja) | 親水性シアニン染料 |